Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

ARTICLE | Product R&D

Enter GammaDelta

How GammaDelta's T cells could become the newest cancer immunotherapy class

Lauren Martz, Senior Writer

September 15, 2016 7:00 AM UTC

Lauren Martz, Senior Writer

Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many years to capitalize on the small subclass that Abingworth believes could outstrip the more common αβ T cells filling company pipelines.

Abingworth will incubate GammaDelta in its London offices and is providing an undisclosed amount of seed funding...

Get Unlimited Access

Continue reading with a free trial.

Start a Free Trial Log In

Or Purchase This Article